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ARTICLE
Two doses of SARS-CoV-2 vaccination induce
robust immune responses to emerging
SARS-CoV-2 variants of concern
Donal T. Skelly 1,2,3,34, Adam C. Harding4,34, Javier Gilbert-Jaramillo 4, Michael L. Knight 4,
Stephanie Longet 5,6, Anthony Brown 1, Sandra Adele1, Emily Adland7, Helen Brown1, Medawar Laboratory
Team*, Tom Tipton 5,6, Lizzie Stafford8, Alexander J. Mentzer 6,8, Síle A. Johnson3,9, Ali Amini 1,3,10,
OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group*, Tiong Kit Tan 11,
Lisa Schimanski11,12, Kuan-Ying A. Huang13, Pramila Rijal11,12, PITCH (Protective Immunity T cells in Health Care
Worker) Study Group*, C-MORE/PHOSP-C Group*, John Frater 1,3, Philip Goulder7,
Christopher P. Conlon 8, Katie Jeffery 3, Christina Dold14,15, Andrew J. Pollard 14,15, Alex Sigal16,17,18,
Tulio de Oliveira17,19,20,21, Alain R. Townsend 11,12, Paul Klenerman1,3,10,15, Susanna J. Dunachie 1,3,22,23,
Eleanor Barnes 1,3,10,15,35, Miles W. Carroll5,6,35 & William S. James 4,35✉
The extent to which immune responses to natural infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against
variants of concern (VOC) is of increasing importance. Accordingly, here we analyse anti-
bodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from
natural infection in early 2020. We show that neutralization of the VOC compared to a
reference isolate of the original circulating lineage, B, is reduced: more profoundly against
B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a
second dose of vaccine. Importantly, high magnitude T cell responses are generated after two
vaccine doses, with the majority of the T cell response directed against epitopes that are
conserved between the prototype isolate B and the VOC. Vaccination is required to generate
high potency immune responses to protect against these and other emergent variants.
https://doi.org/10.1038/s41467-021-25167-5 OPEN
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he emergence of new lineages of SARS-CoV-2 on three
continents towards the end of 2020, and their rapid
expansion at the expense of the previously dominant
lineages, poses significant challenges to public health1. In order to
address these challenges effectively, there is an urgent need to
understand the biological consequences of the mutations found in
these lineages, and the consequential impact on their suscept-
ibility to current control measures, particularly vaccines.
In early 2021, three variants B.1.1.7 (Alpha), B.1.351 (Beta) and
P.1 (Gamma) were identified as variants of concern (VOC1). These
three variants share the N501Y substitution in the receptor-binding
domain (RBD) of spike glycoprotein (S), which increases the
binding affinity of S with the virus’s cellular receptor, angiotensin-
converting enzyme 2 (ACE2)2 (see Fig. 1). As of 1 March 2021,
N501Y is present globally in 77% of currently sequenced samples3.
Lineage B.1.1.7, first identified in the UK in September 2020, is
characterized by additional mutations in S, such as deletion of
residues 69 & 70 and the P681H substitution, for which plausible
effects on the virus biology are proposed, as well as five other
mutations in S, a premature stop codon in ORF8, three substitutions
and a deletion in ORF1 and two amino acid substitutions in
nucleoprotein (N), of as-yet unknown significance. Lineage B.1.3514
was first identified in November 2020 in South Africa and is char-
acterized by two additional substitutions of likely significance in
RBD, namely, K417N and E484K. The former is predicted to disrupt
a salt bridge with D30 of ACE2, a characteristic of SARS-CoV-2 in
distinction to severe acute respiratory syndrome coronavirus (SARS-
CoV-1), but may not impact on binding, whereas the latter, which
might disrupt the interaction of RBD with K31 of human ACE2,
may enhance ACE2 binding2,5. On 1 March 2021, this lineage
accounted for 5% of all current sequences globally, and 100% of
those identified in South Africa. The third variant of concern, P.1
(formerly B.1.1.28.1) is characterized by K417T, in addition to
E484K and N501Y, and accounted for 80% of all viruses sequenced
in Brazil on 1 March 2021. In early 2021, E484K had been detected
first in lineage B.1.1.7 in the United Kingdom (UK)6 and subse-
quently in lineages A23.1, B.1 and B.1.177, as well as in imported
cases of B.1.51 and P.21. Our data confirm that VOC, particularly
those such as B.1.351 with substitutions at residues 484 and 417,
escape neutralization by antibodies directed to the ACE2-binding
Class 1 and the adjacent Class 2 epitopes but are susceptible to
neutralization by the generally less potent antibodies directed to
Class 3 and 4 epitopes on the flanks of the RBD. A futher rapidly
spreading isolate, was recognised as a VOC in May 2021. B.1.617.2
(Delta) was first isolated in India and also shows some evidence of
immune escape, specifically from neutralizing antibodies, but to a
lesser degree than B.1.3517.
The immune correlates of protection against infection and
disease caused by SARS-CoV-2 are imperfectly understood
(reviewed by8,9). Classically, neutralization by antibody, measured
by reduction in plaque or infectious foci by authentic virus
in vitro is considered a major component of protection. Anti-
bodies may also offer protection via fragment crystallizable
(Fc)–Fc receptor interactions10 and harnessing of innate immune
function. Diverse antibody-dependent macrophage, neutrophil,
complement and natural killer cell functions have been demon-
strated after SARS-CoV-2 infection and vaccination11–13. Recent
studies have demonstrated that symptomatic re-infection within
six months after the first wave in the UK was very rare in the
presence of anti-S or anti-N IgG antibodies14,15. Virus-specific
lymphocytes may play an important direct role in protection, in
addition to their indirect role in supporting and driving devel-
opment of antibody-producing cells. Robust T cell immune
responses to S, M, N and some ORF antigens are readily detected
after infection (with CD4 positive cells dominating), correlate
with disease severity and are durable for at least several
months16–18. Furthermore, CD8 depletion studies in non-human
primate (NHP) challenge studies suggest T cells also play a
protective role especially when antibody levels are low19,20,21.
Nevertheless, passive infusion of neutralizing antibody has been
shown to be sufficient to mediate effective protection against
SARS-CoV-2 in these NHP studies20. Although studies in NHPs
of both adenovirus-26 and DNA-based vaccine candidates found
that levels of neutralizing antibodies but not of T cells were sig-
nificantly correlated with viral clearance19,22, recent reports
involving subunit vaccine candidates in NHP found not only
neutralizing antibodies, but also N-specific CD4+ responses were
a statistically significant correlate of protection23.
Fig. 1 Sequence variation in spike glycoprotein. The open reading frame encoding spike (S) is illustrated, with the position of key features of processing
and function indicated to approximate scale (residue number indicated above). During co-translational translocation to the endoplasmic reticulum (ER), the
short leader peptide (LP) is proteolytically removed. Following folding, trimer assembly and glycosylation in the ER and Golgi, the trans-Golgi localized
protease, furin, cleaves the boundary between the S1 and S2 polypeptides. Following binding of the receptor-binding domain (RBD, cyan) to ACE2 on host
cells, cell-surface TMPRSS2 proteolytically cleaves the S2’ site, facilitating conformational changes to spike that result in fusion of the virus envelope with
the plasma membrane. Variant residue positions are indicated below, and their approximate location on the S polypeptide is indicated. Residue identities
are shown at each of these positions for a prototype lineage B isolate, and at each position in four lineages of interest, B.1.1.7 (α—Alpha), B.1.351 (β—Beta),
P.1 (γ—Gamma) and B.1.617 (δ—Delta), at which the respective lineage differs from prototype. Δ indicates deletion of one or more residues. Note,
there are lineage-defining substitutions outside RBD, in the N-terminal domain (NTD) and C-terminal domain (CTD) of S1 (dark blue), and in S2 (tan).
These may include changes that directly or indirectly affect antibody-mediated neutralization or cellular immunity, by loss or altered dynamics of epitope,
respectively.
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Multiple vaccines have been reported to have efficacy against
COVID-19 (coronavirus disease 2019) in phase III clinical trials.
Of these, three—Pfizer/BNT162b2, Moderna/mRNA-1273 and
Sputnik V—that were reported to have efficacies against symp-
tomatic infection in the mid-90% range, had also induced clas-
sical neutralizing antibody titres substantially higher than those
found on average in convalescent patients24–26. In contrast, one—
CoronaVac—that showed ~50% efficacy, had been reported to
induce neutralizing titres several-fold lower than those found in
convalescent patients27. The two remaining vaccines, Sinopharm/
BBIBP-CorV and AstraZeneca/AZD1222 (ChAdOx-1 nCoV-19),
had intermediate values of both clinical efficacy against sympto-
matic infection and relative potency in generating neutralizing
antibody responses11,28. mRNA and adenovirus-vectored vac-
cines generate high magnitude SARS-CoV-2 multispecific CD4+
and CD8+ T cells responses. Reports of vaccines assessed in
South Africa where B.1.351 dominates are currently emerging
and include Ad26.COV2.S (single dose Ad26 vectored vaccine)29,
Novavax (recombinant spike/adjuvant)30, AZD122231 and
BNT162B232,33. With the exception of the recent report on the
Pfizer BioNTech vaccine, each of the studies report reduced
efficacy in South African populations. Vaccine correlates of
protection, and the relative contribution of T cell and humoral
immunity, are yet to be precisely defined since detailed immune
analysis in people with vaccine breakthrough infections is lacking.
In pseudotype virus neutralization assays, it appears that
convalescent sera from patients exposed to prototype strain of
SARS-CoV-2, in distinction to vaccine-elicited responses, may
not be effective in neutralizing lineage B.1.35134,35. As the
lineage-defining substitutions include changes in previously
identified antibody epitopes and regions of S associated with its
processing and rearrangement during cellular infection, this is a
very plausible observation.
Here, in order to test whether convalescent sera and sera
from vaccine recipients are similarly affected in their ability
to neutralize authentic virions, we have undertaken classical
neutralization assays against reference isolates of both B.1.1.7 and
B.1.351 compared to the early pandemic B isolate. We find that,
while cross-neutralization of B.1.1.7 is only modestly reduced
compared to that of the prototype B lineage, cross-neutralization
of B.1.351 may be markedly reduced in convalescent sera, and
after a single vaccine dose. However, both the neutralization of
VOC and the generation of virus-specific T cells, is significantly
enhanced by a boost vaccination. In addition, vaccination not
only induces enhanced reactivity to S from endemic human
betacoronaviruses, but also results in significant cross-reactivity
to both SARS-CoV-1 and Middle East respiratory syndrome-
related coronavirus (MERS-CoV).
Since viral mutations may also affect T cell recognition, we also
evaluate the contribution of T cells that target epitopes located at
sites of amino acid substitution in the spike glycoproteins of
VOC. We show that the majority of T cell responses in recipients
of two doses of the BNT162b2 vaccine are generated by epitopes
that are invariant between the prototype B lineage virus and
VOC. The T cell data are encouraging, and although the weak-
ening of neutralizing antibody titre against VOC might suggest
that further additional SARS-CoV-2 vaccinations with reformu-
lated antigen might be required in the future to address new
variant lineages36, our data support the contention that boosting
with the current vaccines may well provide sufficient protection.
Results
Spike protein sequence differences in SARS-CoV-2 lineages.
The primary structure of the spike glycoprotein (S), and the
characteristic sequence variants of the current three lineages of
concern are illustrated in Fig. 1. In this study, we analysed the
homotypic neutralization of the prototypic, PANGO lineage B
isolate, VIC001 (hereafter referred to simply as ‘B’), by mAbs, sera
from convalescent individuals following SARS-CoV-2 infection,
and recipients of the BNT162b2 (Pfizer) vaccine, which are each
induced by prototypic S antigen. We then assessed heterotypic
neutralization of two VOC (B.1.1.7 and B.1.351). In Fig. 1, we
indicate the residues of S at which the respective lineage—as well
as two further lineages of concern, P.1 and B.1.617.2—differ from
lineage B.
SARS-CoV-2 binding antibodies and ACE2-spike binding
inhibition. We probed the antibody-binding properties of sera
from vaccinated, convalescent and pre-pandemic control sera using
a customised Mesoscale Discovery (MSD) coronavirus antigen
immunoassay (Fig. 2). We observed that sera from individuals
receiving two doses of the Pfizer vaccine showed a non-significant
increase in binding to SARS-CoV-2 spike and RBD compared to
those receiving single dose and a significant difference from sera of
convalescent individuals one month after infection (Fig. 2a and b,
respectively, P < 0.0001 in all cases by Kruskal–Wallis one-way
ANOVA with Dunn’s multiple comparisons tests). The absence of
N binding in vaccinees (Fig. 2c) supports the designation of these
individuals as SARS-CoV-2 unexposed, although it does not prove
absence of the previous infection.
There was significant antibody binding to both SARS-CoV-1 and
MERS-CoV spike protein in vaccinated and COVID-19 convales-
cent individuals compared to the pre-pandemic control sera (Fig. 2d
and e, respectively). This was particularly marked for SARS-CoV-1
reactivity in fully vaccinated individuals, suggesting that the vaccine
can induce a broad response to widely shared epitopes, such as
those exemplified by EY 6A40 and CR302245.
We also screened for antibody binding to the spike antigen of
the four common circulating coronaviruses (Fig. 2f–i). There is a
significant increase in binding to the Betacoronavirus clade A
isolates, HCoV-HKU1 and HcoV-OC43, in vaccinated and
COVID-19 convalescent sera (P < 0.0001) compared to unvacci-
nated naive sera. Binding to the Alphacoronavirus isolates, HcoV-
229E and, to a lesser extent, HcoV-NL63S was also greater in the
vaccinees, but not in convalescent sera.
As a surrogate to neutralization, we assessed the ability of sera
to inhibit ACE2-spike binding using MSD plates printed with
spike proteins representing the prior circulating B lineage, and the
more recently evolved VOC (B.1, B1.1.7, B1.351 and P.1).
Figure 2j indicates that serum from vaccinated individuals
receiving either single or double vaccination was able to inhibit
ACE2 binding of SARS-CoV-2 spike. The inhibitory effect was
significantly higher, (P < 0.001 by Mann–Whitney comparisons)
in those sera derived from individuals sampled after receiving the
boost vaccination compared to post-prime samples. Fold changes
in mean inhibitory activity between post-prime and post-boost
ranged from 49 for B.1 to 18 for B.1.351. Following vaccine boost,
the mean inhibitory activity of B differs significantly from B.1.351
and P.1 but not B.1.1.7 (Friedman test, P < 0.0001).
Neutralization by monoclonal antibodies and reference
plasma. We made use of a panel of six, epitope-mapped neu-
tralizing monoclonal antibodies (NmAbs, Fig. 3a,)42,43,46,47 in
order to map the neutralization sensitivity of VOC to changes in
RBD epitopes. We have devised a ‘squirrel’ diagram to help
visualise the binding sites of the various mAbs on the RBD
(Fig. 3a). One NmAb, FI 3A, a Class 1 RBD monoclonal antibody
(binds to the left side of the head of the squirrel), whose homo-
typic half-maximal inhibitory concentration (IC50) is of the order
of 1 nM, is largely unaffected by the changes in B.1.1.7
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Fig. 2 Binding assays. IgG antibodies specific to; a–c SARS-CoV-2 (spike [S], receptor-binding domain [RBD], nucleocapsid [N]), d, e SARS-CoV-1 S,
MERS-CoV S, f–i HCoV-OC43 S, HCoV-HKU1 S, HCoV-229E S, HCoV-NL63 S, were measured using an MSD technology platform customised array. Sera
analysed were from vaccinees (post-prime and post-boost), asymptomatic (mean 27 days post-PCR positive test, range 22–33 days) and mild COVID-19
convalescent sera (mean 29 days post-symptom onset, range 18–40 days) and a cohort of prepandemic sera collected between 2014 and 2018 negative
for SARS-CoV-2 (negatives). Data are displayed as calculated concentrations which use an MSD standard reference curve to interpret arbitrary units (AU).
Statistical difference between the groups was performed using a two-tailed Kruskal–Wallis one-way ANOVA with Dunn’s post-test for multiple
comparisons made to compare all groups (significant adjusted P values are displayed). Vaccinees post-prime n= 11; vaccinees post-boost n= 25; negatives
n= 103; asymptomatic COVID-19 convalescents n= 11; mild COVID-19 convalescents n= 62. The dashed lines in a–c show the cut-offs determined as the
mean of negatives +3 SD. Samples were run in monoplicate (convalescent samples) or duplicates (vaccine samples). j Inhibition analysis between ACE2
and recombinant spike from the designated homotypic and heterotypic lineages. Sera derived from individuals receiving prime or boost vaccination: post-
prime n= 11, post-boost n= 18–25 dependent on spike variant. Differences between B and other variants in post-prime and post samples were tested using
a Friedman statistical test with Dunn’s multiple comparison test (significant P values are displayed on lines linking B to variant). A two-tailed
Mann–Whitney U test was used to compare post-prime and post boost groups for each variant. P values are displayed on the boost panel, immediately
above each variant and are italicized. Plots show median with error bars indicating ± intraquartile range) (IQR). ACE2 inhibition assay samples were run in
monoplicate.
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(IC50= 1.365 nM) but does not neutralize B.1.351. Two other
NmAbs, GR 12C and C121, that are Class 2 RBD binding mAbs
(binding to the right side of the head of the squirrel), and which
have homotypic IC50 ~0.1 nM, show some reduced effectiveness
in neutralizing B.1.1.7 and have lost almost all potency against
B.1.351. This might be expected, as class 2 antibodies bind to an
epitope that includes residue 484 (reviewed by refs. 47,48). In
contrast, NmAb FD 11A and S309, which are Class 3 RBD mAbs,
that bind to the right haunch of the squirrel, and EY 6A, Class 4
monoclonal antibody, that binds to the left haunch of the squirrel,
appear to be unaffected by the mutations in the VOC. Polyclonal
responses generated by different individuals to natural infection
or in response to vaccination may include a varying proportion of
antibodies to these and other neutralization epitopes.
B Prime Boost asymptomMild
Prime 1 0.000005 0.358379 0.00314
Boost **** 1 0.000002 0.114454
Asymptomac ns **** 1 0.002342
Mild ** ns ** 1
B.1.1.7 Prime Boost asymptomMild
Prime 1 0.000002 0.998653 0.000691
Boost **** 1 0.000002 0.061535
Asymptomac ns **** 1 0.000481
Mild *** ns ** 1
B.1.351 Prime Boost asymptomMild
Prime 1 0.000005 >0.999999 0.271948
Boost **** 1 0.000002 0.001379
Asymptomac ns **** 1 0.248548
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Figure 3b shows the performance of NIBSC 20/130 plasma on
our MNA. The use of this international standard enables calibration
of assay sensitivity with other published works and serves as a
reliable positive control. The expected NT50 of this standard against
the B isolate, as stated in the accompanying data sheet, is 1:1280.
Our own result demonstrates consistency with this expectation
(918.2; 95% CL 729.6–1165). Of note, neutralizing activity of this
plasma is substantially diminished against both B.1.1.7 (125; 95%
CL 86–164), and B.1.351 (14; 95% CL 0.1–51). Serum derived from
non-infected, unvaccinated individuals acted as negative controls.
These naive samples demonstrate the absence of any background
neutralization (Supplementary Fig. 2a).
Neutralization by sera from COVID-19 convalescents. Sera
from convalescent individuals neutralized prototype B virus with
highly variable potency (NT50 range <5 to 1140, Fig. 3c and e),
though sera from those with mild symptoms were significantly
more potent on average than those with asymptomatic infection
(NT50 438.4 and 38.5, respectively, P= 0.002). Neutralization
titres against B.1.1.7 were below the limit of detection in 9/12
asymptomatic convalescent individuals but were detectable in all
those with mild symptoms. The neutralizing potency of mild
convalescent sera against B.1.1.7 was significantly greater than
that of asymptomatic sera (NT50 133 and 9.3, respectively;
Kolmogorov–Smirnov test, P= 0.0005).
The decline in neutralization potency was more marked against
the B.1.351 isolate, with convalescent sera from 12/12 asymptomatic
and 7/12 mild having undetectably low neutralizing potency.
Although there was no significant difference between the mean
NT50 of mild versus asymptomatic sera against B.1.351 (119 and <5
respectively, P= 0.25), the reduction in potency overall in relation
to prototype B virus was very significant (P= 0.000003).
Neutralization by sera from vaccine recipients. After a single
dose of BNT162b2 vaccine, homotypic neutralization potency was
on average comparable to that of an asymptomatically infected
cohort (NT50 53.8 and 38.5, respectively, P= 0.36), but lower than
sera from those who had recovered from mild infection (NT50
438.3, P= 0.003; see Fig. 3d and e). Neutralization after one dose
was undetectable against B.1.1.7 in 7/11 samples, and in all 11 sera
tested against B.1.351.
Sera drawn between 7 and 17 days after a second dose of
BNT162b2 vaccine—administered 18–28 days after the first dose—
neutralized lineage B virus with high potency (average NT50= 768)
and 23/25 individuals had NT50 >> 1/100, (Fig. 3d), whereas 2/25
individuals showed more modest titres (10 <NT50 < 100). These
sera neutralized the B.1.1.7 isolate with a significantly lower potency
(average NT50= 320; P < 0.0001, Kolmogorov–Smirnov test); the
same 23/25 had NT50 titres > 100 and 2/25 NT50 titres 10–100.
The decline in neutralization potency against the B.1.351 isolate
was further significantly reduced (NT50= 171; P= 0.000001), but
12/25 retained NT50 titres > 100, 11/25 NT50 10–100 with only the
2/25 with modest homotypic neutralization potency having
undetectable heterotypic neutralizing potency.
The relationship of the neutralizing titre of each individual’s
serum to B to the corresponding titre against each variant apparent
in Fig. 3d is significant. Spearman correlation coefficients (r) are:
0.76 (B to B.1.1.7, CL 0.52–0.98; P= 0.0000092); 0.74 (B to B.1.351,
CL 0.48–0.88. P= 0.00002); and 0.79 (B.1.1.7 to B.1.351, CL
0.57–0.91, P= 0.000002).
T cell responses to spike antigens in B strain and VOC. Fol-
lowing two doses of BNT162b2, spike-specific T cells were
detected in all individuals against spike antigens covering the
prototypic B strain, assessed in IFN-γ ELISpot assays peaking
7 days after the second vaccine (mean magnitude 561, range
110-1717 SFC/106 PBMC) (Fig. 4a and Supplementary Fig. 4).
Spike-specific T cells could not be detected in unvaccinated
SARS-CoV-2 unexposed HCW (Supplementary Fig. 3). This
is in keeping with our previously published work14 demon-
strating our highly specific IFN-γ ELISpot assay, which yields
negligible T cell responses detected to specific peptides in
unexposed subjects with the selected peptide concentrations
and incubation time.
Assessing the contribution of T cells that target epitopes located
at the site of B.1.1.7, B.1.351 and P.1 spike mutation sites, we find
that T cells target epitopes spanning mutation sites in 18/24
individuals (Fig. 4b). In each individual, T cells targeted 0–19 (mean
6) epitopes located at mutation sites (Supplementary Table 2) with a
total of 8, 9 and 10 epitopes targeted in lineage B.1.1.7, B.1.351 and
P.1 respectively. The overall contribution of T cells targeting
mutation regions to the total spike specific response is (mean and
range) 13% (0–67%) for B.1.1.7, 14% (0–44%) for B.1. 351 and 10%
(0–29%) for P.1 (Fig. 4c). Although the overall contribution of T cell
responses to mutational regions/total spike responses was low,
in general multiple individuals had T cells that targeted each
of the mutational regions, spanning all spike domains (Fig. 4d and
Fig. 3 Homotypic and heterotypic neutralization of key SARS-CoV-2 lineages by antibody. The potency of neutralization was determined by a focus-
forming unit microneutralization assay against authentic virus of prototype B lineage and isolates of B.1.1.7 and B.1.351. a A cartoon of a ‘squirrel’ illustrating
the receptor-binding domain (RBD). Markings on the squirrel show the epitopes of the RBD antibodies used in this study (classes 1–447). Neutralization by
the panel of monoclonal antibodies binding to four distinct epitopes of RBD (upper left). A space-filling model of prototype RBD (PDB 6YZ5) created in
PyMOL, shows the residue of the mutations present in the B.1.1.7 and B.1.351 lineages in blue (upper middle and upper right; same aspect and reverse
aspect as the space-filling model, respectively). b Neutralization by the international reference plasma NIBSC 20/13038, nominally NT50= 1/1000. The
mean number of foci ± SD relative to a no-antibody control is plotted against the reciprocal of the respective serum dilution. Data were fitted by non-linear
regression in GraphPad Prism 9 to the Hill Equation, with TOP and BOTTOM constrained to 100 and 0%, respectively. Where a significant fit was obtained,
it is represented by a trend line on the respective plot, and NT50 values used in Supplementary Fig. 1 and main results. NT50 against B established in our
assay indicated by the vertical dashed line with grey bars indicating the 95% confidence interval. c Neutralization by convalescent sera from asymptomatic
participants (left) and those with mild symptoms (right) against B, B.1.1.7 and B.1.351 isolates. A Tukey’s multiple comparison test was performed for each
serum group, comparing mean NT50 response to each virus isolate. P values of all comparisons are displayed in the figures. d Neutralization by sera from
recipients of a single dose (left) and both prime and boost doses (right) of BNT162b2 vaccine. e Homotypic and heterotypic neutralization potencies of the
three sources of antibody against the three isolates, shown by individual (dots) and sub-population mean and SD of NT50 values shown with error bars
(upper panel). For each isolate, pairwise comparisons of average NT50 estimates were made between groups of serum using the Kolmogorov–Smirnov
non-parametric test. P values for the r statistic are shown (lower panel), both numerically and symbolically. P > 0.05 in green and ‘ns’. No results for 0.05 >
P > 0.01. 0.01 > P > 0.001 in yellow and **P < 0.001 in red and ****. Vaccinees post-prime n= 11; vaccinees post-boost n= 25; asymptomatic COVID-19
convalescents n= 12; mild COVID-19 convalescents n= 13. MNA tests were performed in quadruplicate for all samples. Each plate contained serum-free
controls for normalization of results.
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Fig. 4 ELISpot responses to prototype, B.1.1.7, B.1.351 and P.1. T cell responses were measured using IFN-γ ELISpot assays in 24 healthy volunteers,
7–17 days after receiving the 2nd dose of BNT162b2. a T cell responses to 15–18-mer peptides in B strain overlapping by 10 amino-acids and spanning the
entire spike region. b Summed T cell responses to peptides from B strain that mapped to sites with mutations in B.1.1.7 (n= 17 peptides), B.1.351 (n= 21
peptides) and P.1 (n= 22 peptides). c Percentage contribution T cells (using B peptides) that target mutational regions within B.1.1.7, B.1.351 and P.1, relative
to the total T cell spike response in each of the 24 volunteers. d T cell responses to 22 individual peptides in B strain that have corresponding mutations in
B.1.1.7, B.1.351 and P.1 variants. Standardised ELISpot assays were run in triplicate for background and spike peptides and duplicates for all others to allow
cell preservation. DMSO control with matching percent DMSO was also used in all assays to account for DMSO content in peptide pools. Each bar
represents one volunteer with a positive response (defined as a response to the peptide minus the background that was greater than twice the
background). SFC/106 PBMC= spot forming cells per million peripheral blood mononuclear cells, with background subtracted.
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Supplementary Table 2). T cell responses to total spike and
mutation sites were further assessed in a small number of vaccinees
after only a single vaccine; here low magnitude T cell responses
were detected (Supplementary Fig. 5a), with T cells targeting
mutational regions in 3/5 vaccinees (Supplementary Fig. 5b).
Similar to post boost responses, the relative contribution of these to
total spike was low (% mean contribution and range; 24% (2–34%)
for B.1.1.7, 11% (0–20%) for B.1. 351 and 7% (0–23%) for P.1)
(Supplementary Fig. 5c).
Prediction of neutralization by immunoassay binding. Authentic
virus neutralization assays require specialist staff and facilities that are
not widely available, and access to reference isolates of virus that are
laborious to distribute. Accordingly, we asked whether high
throughput ELISA-style immunoassays could provide a degree of
predictive value for heterotypic neutralization following vaccination
or previous infection. We performed Spearman non-parametric
correlation analysis between the neutralization, spike-binding, and
inhibition of ACE2-spike binding results obtained from the same
sera, as detailed in the foregoing sections.
The results show that there is a significant correlation (P <
0.0001) between spike-binding and neutralization of authentic virus
across samples drawn from participants after 1 and 2 doses of
vaccine, and previous infection (Fig. 5a). The Spearman r between
neutralization by serum of lineage B virus and the binding activity
to lineage B RBD is 0.74 (95% CI 0.6–0.8, n= 56, P= 1 e−10), and
the r between neutralization of lineage B.1.351 and binding to B
RBD is 0.75 (0.6–0.8, n= 56, P= 3 e−11). These relationships hold
for post-boost comparisons (Supplementary Fig. 6), and compar-
ison in convalescents after infection (Supplementary Table 3a but
do not hold strongly in post-prime comparisons alone (Supple-
mentary Table 3b). Interestingly, binding activity to SARS-CoV-2 S
predicted binding to both SARS-CoV-1 S and MERS-CoV S very
well (r= 0.94 (0.90–0.96), n= 56, P= 2 e−27; and r= 0.59
(0.4–0.7), n= 56, P= 1 e−6). Moderate correlations (r of the
order of 0.5) were seen with binding to the spike of endemic human
betacoronaviruses and HCoV-229E, but not to that of HCoV-NL63.
We assessed inhibition of ACE2-spike binding in the sera of
vaccinated participants (Fig. 5b). The correlation between
neutralization and inhibition ACE2-spike binding is similar, with
r= 0.67 (0.4–0.8, n= 35, P= 0.00007) for lineage B, and r= 0.79
(0.6–0.9, n= 35, P= 2 e−8) for lineage B.1.351 It is important to
note that, in this assay, the spike sequences correspond to the
virus lineage in the neutralization assay.
No significant correlations were observed between humoral
and T cell responses to whole S protein, determined by ELISpot
analysis in those who had received two vaccine doses.
Discussion
Our results show that both binding and neutralization by antibodies
induced by the S protein of prototypic lineage B is diminished to S
from recent VOC; B.1.351 to a greater extent than B.1.1.7. This
broad trend masks both qualitative and quantitative differences
in antibody responses by individuals, whose serum may contain
differing proportions of antibodies to neutralizing epitopes that we
show here are sometimes conserved between lineages.
Given the cost and difficulty of authentic virus neutralization
assays, it is encouraging that in our hands, both a high-
throughput spike-binding assay and a spike-ACE2 binding-inhi-
bition assay provide a significant correlation with the neutralizing
potency—both homotypic and heterotypic—of sera after two
doses of vaccine (BNT162b2). It is perhaps not surprising that in
post-prime sera, this relationship is much weaker, given our
current understanding of the distribution of the neutralization
epitopes on the spike glycoprotein (see Fig. 2a) and maturation of
the immunoglobulin response. For example, neutralizing anti-
bodies that compete for ACE2 binding tend to lie in class 1 and 2,
whose epitopes are subject to VOC-associated substitutions,
whereas neutralization epitopes of class 3 and 4 do not overlap
with the ACE2 binding site and are conserved in most isolates.
It is also reassuring to find that the majority of T cell responses
in recipients of two doses of the BNT162b2 vaccine are generated
by epitopes that are invariant between the prototype and two of
the current VOC (B.1.1.7 and B.1.351). These data are compatible
with a recent report that the sequences of the vast majority of
Fig. 5 Cross-correlation of immune parameters. For each serum, pairwise
Spearman correlation analyses were undertaken between the value of
binding of serum antibody to coronavirus antigens, the ACE2-spike
binding-inhibition potency (see Fig. 2), and the homotypic and
heterotypic neutralizing titre of the same sera (see Fig. 3). a Heatmap of
two-tailed Spearman’s r parameter for each comparison in which spike
binding data was available across samples drawn from participants after
1 dose (n= 11, mean 27 days after the 1st dose) and 2 doses of
BNT162b2 vaccine (n= 25, mean 8 days after receiving the 2nd dose),
and previous infection (n= 20, 11:9 asymptomatic to symptomatic,
mean 28 days since PCR test for asymptomatics or symptoms onset).
Colour mapping is dual gradient from Blue (r= 1.0) through White
(r= 0.5) to Red (r= 0). Values outside this range are Black. b Heatmap
Spearman’s r parameter for each comparison in which ACE2-spike
binding-inhibition data were available (n= 35:11 after the 1st dose and
24 after the 2nd vaccine dose). Colour mapping as in (a).
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SARS-CoV-2 T cell epitopes are not affected by the mutations
found in the B.1.1.7 or B.1.351 variants49, with no significant
differences observed in CD4 and CD8 responses to a pool of S
peptides corresponding to the ancestral sequence and those cor-
responding to the different variants. T cell responses to SARS-
CoV-2 are known to target a wide range of regions in spike50.
Consistent with this, our data show that neutralization of sera and
T cell activity are independent22. Moreover, in over 90% of the
recipients of two vaccine doses, heterotypic neutralizing titres
(NT50) remain comfortably above the level associated with
immune protection in non-human primate challenge studies19,22.
However, in a majority of individuals whose homotypic neu-
tralization titres were more modest—including over 50% of
convalescent COVID-19 individuals and recipients of a single
dose of vaccine—heterotypic neutralization dropped to negligible
levels. This loss of cross-neutralization was particularly notable
against B.1.351 with potential implications for vaccine effective-
ness in populations where this VOC dominates and when only
moderate levels of S antibodies are generated after vaccination.
It should be noted that neutralization escape, observed in a well of
a micro-titre plate, is not direct evidence of vaccine failure. Non-
neutralizing antigen-specific antibodies, T cells and innate lympho-
cytes clearly have the potential to contribute to vaccine efficacy51. The
acceptance that prior infection with influenza virus results in reduced
disease against subsequent infection with heterosubtypic strains, in
both human and animal challenge studies, provides further evidence
that cellular components and non-neutralizing antibodies make an
important contribution to protection52–54. We also note that the
recent South African and UK vaccine clinical trials for Novavax
reportedly showed 60 and 85.6% protective efficacy against infection
for the B.1.351 and B.1.1.7 VOC, respectively, with no cases of vac-
cinated individuals requiring hospitalization due to severe disease55.
Ongoing analysis of real-world vaccine roll out will illuminate the
extent of vaccine breakthrough with VOC, although there is already
evidence that two-dose regimen of AZD1222 does not protect against
mild-to-moderate COVID-19 caused by B.1.35156.
Nevertheless, our results re-emphasize the urgent need to
deploy the most effective vaccine strategies as widely and rapidly
as possible in order to provide population protection against the
emerging lineages of concern of SARS-CoV-2. Our findings show
clearly that the weaker responses generated for example by nat-
ural infection or single doses of vaccine, do not provide adequate
cross-neutralization. The results support the recommendations by
Pfizer, the FDA and EMA for a two-dose vaccine regimen.
Methods
Volunteer samples. Volunteers were recruited at Oxford University Hospitals
NHS Foundation Trust in ethically approved studies. Healthcare Workers (HCWs)
with asymptomatic SARS-CoV-2 infection, defined as being SARS-CoV-2 poly-
merase chain reaction (PCR) positive on screening without symptoms (mean
28 days post-PCR testing, range 24–34 days) and mild symptomatic COVID-19,
defined as being SARS-CoV-2 PCR positive and having symptoms not requiring
O2 support/hospitalization (mean 28 days post-symptom onset, range 24–37 days)
were recruited under the OPTIC Study: Oxford Translational Gastrointestinal Unit
GI Biobank Study 16/YH/0247 [REC at Yorkshire & The Humber—Sheffield].
HCWs not known to be previously infected with SARS-CoV-2, were recruited after
vaccination with the COVID-19 mRNA Vaccine BNT162b2 (Pfizer). 11 partici-
pants were recruited post-prime (mean 29 days after a single dose, range 18–41). 25
participants were recruited post-boost (mean 8 days after the second dose, range
7–17 days) and assessed again for T cell reactivity 28 days boost. An additional 13
unvaccinated, non-SARS-CoV-2 exposed HCW were recruited and assessed for T
cell reactivity. Four unvaccinated participants were recruited under the Observa-
tional Biobanking study approvals SthObs (18/YH/0441) and assessed for neu-
tralizing antibodies. Pre-pandemic negative control sera, used for binding assays,
were obtained from a prior vaccine study of the National Vaccine Evaluation
Consortium, performed in 2017. Ethics approval from NHS Heath Research
Authority—NRES committee London City and East 2017. Supplementary Table 1
shows summary details for each group in terms of days since vaccination or
infection and the assays were performed. The study was conducted according to the
principles of the Declaration of Helsinki (2008) and the International Conference
on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. Written
informed consent was obtained for all patients enrolled in the study.
Virus isolates. Prototype isolate (PANGO lineage B) was Victoria/01/202037, received
at P3 from Public Health England (PHE) Porton Down (after being supplied by the
Doherty Centre Melbourne) in April 2020, passaged in VeroE6/TMPRSS2 cells (NIBSC
reference 100978), used here at P5, and confirmed identical to GenBank MT007544.1, B
hCoV-19_Australia_VIC01_2020_ EPI_ ISL_ 406844_ 2020-01-25. B.1.1.738, (20I/
501Y.V1.HMPP1) isolate, H204820430, 2/UK/VUI/1/2020, received in Oxford at P1
from PHE Porton Down in December 2020, passaged in VeroE6/TMPRSS2 cells, used
here at P4. B.1.351 (20I/501.V2.HV001) isolate39 was received at P3 from the Centre for
the AIDS Programme of Research in South Africa (CAPRISA), Durban, in Oxford in
January 2021, passaged in VeroE6/TMPRSS2 cells, used here at P4. For all isolates,
identity was confirmed by deep sequencing at the Wellcome Trust Centre for Human
Genetics, University of Oxford.
Microneutralization assay (MNA). The study was performed in the containment
level 3 facility of the University of Oxford, operating under license from the Health
and Safety Authority, UK, on the basis of an agreed code of practice, risk assess-
ments (under the Advisory Committee on Dangerous Pathogens guidance) and
standard operating procedures. The microneutralization assay determines the
concentration of antibody that produces a 50% reduction in infectious focus-
forming units (FFU) of authentic SARS-CoV-2 in Vero cells (ATCC CCL-81.
Quadruplicate serial dilutions of serum, or monoclonal antibody (20 μL), were
preincubated with 100-200 FFU (20 μL) of SARS-CoV-2 for 30 min at room
temperature. After pre-incubation, 100 μL of Vero CCL-81 cells (4.5 × 104) were
added and incubated at 37 °C, 5% carbon dioxide. After 2 h, 100 μL of a 1.5%
carboxymethyl cellulose-containing overlay was applied to prevent satellite focus
formation. Eighteen (B.1.351) or 23 h (B, B.1.1.7) post-infection, the monolayers
were fixed with 4% paraformaldehyde, permeabilized with 2% Triton X-100 and
stained for the nucleocapsid (N) antigen or spike (S) antigen, using monoclonal
antibodies (mAbs) EY 2A and EY 6A, respectively (both used at 1ug/mL)40. After
development with a peroxidase-conjugated antibody (1:5000 dilution, cat. no.
A0170-1ML, Sigma-Aldrich, Germany) and TrueBlue peroxidase substrate, infec-
tious foci were enumerated by ELISpot reader. Data were analysed using four-
parameter logistic regression (Hill equation) in GraphPad Prism 8.3.
Expression and purification of monoclonal antibodies. Monoclonal antibodies FI
3A (Class 1), GR 12C (Class 2), FD 11A (Class 3) and EY 6A (Class 4) were isolated
from convalescent patients as previously described40. In brief, plasmablasts from hos-
pitalised PCR-confirmed SARS-CoV-2 infected patients (day 14 to day 22 post onset of
symptoms) were isolated. Freshly separated or thawed PBMCs were stained with
fluorescent-labelled antibodies to cell surface markers; Pacific Blue anti-CD3 (clone
UCHT1, cat. no. 558117, 420 BD), fluorescein isothiocyanate anti-CD19 (clone HIB19,
cat. no. 555412, BD), 421 phycoerythrin-Cy7 anti-CD27 (clone M-T271, cat. no.
560609, BD), 422 allophycocyanin-H7 anti-CD20 (clone L27, cat. no. 641396, BD),
phycoerythrin423 Cy5 anti-CD38 (clone HIT2, cat. no. 555461, BD) and phycoerythrin
anti-human IgG (clone G18-145, cat. no. 555787, BD). The CD3neg CD19pos CD20neg
CD27hi CD38hi IgGpos plasmablasts were gated as single cells.
Sorted single cells were used to produce human IgG mAbs, as previously
described41. Briefly, the variable region genes from each single cell were amplified
in a reverse transcriptase-polymerase chain reaction (RT-PCR: QIAGEN,
Germany) using a cocktail of sense primers specific for the leader region and
antisense primers to the Cγ constant region for heavy chains and Cκ and Cλ for
light chains. The RT-PCR products were amplified in separate PCR for the
individual heavy and light chain gene families using nested primers to incorporate
unique restriction sites at the ends of the variable gene as previously described41.
Monoclonal antibodies C121 (Class 2) and S309 (Class 3) were derived from the
published sequences42,43 by gene synthesis (GeneArt). These variable genes were
then cloned into expression vectors for the heavy and light chains. Plasmids were
transfected into the Expi293F cell line for expression of recombinant full-length
human IgG mAbs in serum-free transfection medium. The mAbs were then affinity
purified using a MabSelectSure column (Cytiva, USA), according to the
manufacturer’s protocol and buffer exchanged into 1xPBS using a 10k molecular
weight cut off. Amicon Ultracentrifugal Unit.
National Institute for Biological Standards and Control (NIBSC) 20/130
reference plasma was obtained from the NIBSC, UK. It is human plasma from a
donor recovered from COVID-19.
Mesoscale discovery (MSD) binding assays. IgG responses to SARS-CoV-2,
SARS-CoV-1, MERS-CoV and seasonal coronaviruses were measured using a mul-
tiplexed MSD immunoassay: The V-PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit
(cat. no. K15399U) from Meso Scale Diagnostics, Rockville, MD USA. A MULTI-
SPOT® 96-well, 10 spot plate was coated with three SARS CoV-2 antigens (S, RBD,
N), SARS-CoV-1 and MERS-CoV spike trimers, as well as spike proteins from sea-
sonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-
NL63, and bovine serum albumin. Antigens were spotted at 200−400 μg/mL (MSD®
Coronavirus Plate 3). Multiplex MSD assays were performed as per the instructions of
the manufacturer. To measure IgG antibodies, 96-well plates were blocked with MSD
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Blocker A for 30min. Following washing with washing buffer, samples diluted
1:500–10,000 in diluent buffer, or MSD standard or undiluted internal MSD controls,
were added to the wells. After 2-h incubation and a washing step, detection antibody
(MSD SULFO-TAG™ Anti-Human IgG Antibody, 1/200 dilution, cat. no. D21ADF-3)
was added. Following washing, MSD GOLD™ Read Buffer B was added and plates
were read using a MESO® SECTOR S 600 Reader. The standard curve was established
by fitting the signals from the standard using a 4-parameter logistic model. Con-
centrations of samples were determined from the electrochemiluminescence signals
by back-fitting to the standard curve and multiplied by the dilution factor. Statistical
analysis was performed using Kruskal–Wallis one-way ANOVA.
A multiplexed MSD immunoassay (MSD, Rockville, MD) was also used to
measure the ability of human sera to inhibit ACE2 binding to SARS-CoV-2 spike
(B, B.1, B.1.1.7, B.1.351 or P.1). A MULTI-SPOT® 96-well, 10 spot plate was coated
with five SARS-CoV-2 spike antigens (B, B.1, B.1.1.7, B.1.351 or P.1). Multiplex
MSD Assays were performed as per manufacturer’s instructions. To measure ACE2
inhibition, 96-well plates were blocked with MSD Blocker for 30 min. Plates were
then washed in MSD washing buffer, and samples were diluted 1:10–1:100 in
diluent buffer. Importantly, an ACE2 calibration curve that consists of a
monoclonal antibody (cat. no. C01ADG-2) with equivalent activity against spike
variants was used to interpolate results as arbitrary units. Furthermore, internal
controls and the NIBSC 20/130 international standard were added to each plate.
After 1-h incubation recombinant human ACE2-SULFO-TAG™ was added to all
wells. After a further 1-h plates were washed and MSD GOLD™ Read Buffer B was
added, plates were then immediately read using a MESO® SECTOR S 600 Reader.
Peptides used in IFN-γ ELISpot assays. Peptides corresponding to SARS-CoV-2
prototype lineage B isolate, VIC01, 15–18 amino-acids overlapping by 10 amino-
acids and spanning the entire spike region, were used in IFN-γ ELISpot assays.
Spike peptides were used in two pools (S1 and S2) (Mimotopes, Victoria Australia).
Cytomegalovirus, Epstein-Barr virus, influenza and tetanus antigens (CEFT) were
used in single pools as positive control antigens (2 µg/mL: Proimmune, Oxford,
UK). Single peptides (Mimotopes, Victoria Australia) that mapped to sites con-
taining substitutions in lineages B.1.1.7 (n= 17), B.1.351 (n= 21) and P.1 (n= 22),
with reference to B, were used in single peptides or pooled by individual VOC.
T cell responses to original B strain peptides covering the areas of known sequence/
amino acid mutations/deletions in the VOC (B.1.1.7, B.1.351 and P.1) relative to B
are assessed. Three peptides, each of which span a single mutational site/region,
were used in these assays: (i) firstly in pools to cover all mutation regions within
each VOC and then (ii) mapped to single mutational regions. T cell responses to
the peptide pools that span the mutational regions are also assessed alone and in
relation to the total T cell response against the entire spike antigen.
IFN-γ T cell ELISpot assays. Peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation using LymphoprepTM (p= 1.077 g/mL,
Stem Cell Technologies), washed twice with RPMI (Roswell Park Memorial
Institute)-1640 (Sigma, St. Louis, MO, USA) containing 10% heat-inactivated fetal
calf serum (Sigma), 1 mM Pen (100 U/ml)/Strep (100 μg/ml) and 2 mM
L-glutamine (Sigma) and resuspended in R10 and counted using the Guava®
ViaCountTM assay on the Muse Cell Analyzer (Luminex Cooperation). PBMCs
were frozen and stored in liquid nitrogen before use.
As previously described44, 96-well Multiscreen-I plates (Millipore, UK) were
coated for 3 h with 10 μg/mL GZ-4 anti-human IFN-γ (Mabtech, AB, Sweden) at
room temperature. PBMC were added at 2 × 105 cells in 50 μL per well and
stimulated with 50 μL of SARS-CoV-2 peptide pools (2ug/mL per peptide) in
duplicate. R10 with dimethyl sulfoxide (DMSO) (final concentration 0.4%, Sigma)
was used as negative control and CEFT ((2 µg/mL, Proimmune)/ Concanavalin A
(ConA, 5 µg/mL final concentration, Sigma) were used as positive control antigens.
After 16–18 h at 37 °C PBMC were removed and secreted IFN-γ detected using
anti-IFN-γ biotinylated mAbs at 1 μg/mL (7-B6-1-biotin, Mabtech) for 2–3 h,
followed by streptavidin alkaline phosphatase at 1 μg/mL for 1–2 h (SP-3020,
Vector Labs). The plates were developed using BCIP/NBT (5-bromo-4-chloro-3-
phosphatase/nitro blue tetrazolium) substrate (Thermo Scientific/Pierce
Biotechnology, Rockford, Il) according to the manufacturer’s instructions. ELISpot
plates were read using an AID ELISpot Reader (v.4.0). Results were reported as
spot-forming units (SFU)/106 PBMC, with a positive control ConA response of
>400 SFU/106 PBMC observed for all assays. Background (mean SFU in negative
control wells) was subtracted from antigen stimulated wells to give the final result.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data generated in this study are provided in the Supplementary Information/Source
data file. Source data are provided with this paper.
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